Stockscreener 앱 받기
3.21
3.60%
-0.12
시간 외 거래:
3.22
0.01
+0.31%
전일 마감가:
$3.33
열려 있는:
$3.37
하루 거래량:
441.59K
Relative Volume:
0.76
시가총액:
$48.22M
수익:
-
순이익/손실:
$-64.47M
주가수익비율:
-0.519
EPS:
-6.1852
순현금흐름:
$-52.33M
1주 성능:
-7.49%
1개월 성능:
-37.67%
6개월 성능:
-43.68%
1년 성능:
-84.14%
1일 변동 폭
$3.1408
$3.38
1주일 범위
$3.1408
$3.53
52주 변동 폭
$2.265
$26.05
Jasper Therapeutics Inc Stock (JSPR) Company Profile
명칭
Jasper Therapeutics Inc
전화
(650) 549-1400
주소
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
JSPR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
3.21 | 52.13M | 0 | -64.47M | -52.33M | -6.1852 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-08 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-07-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-07-07 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-02-13 | 개시 | UBS | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-09-09 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-08 | 개시 | BTIG Research | Buy |
| 2024-06-27 | 개시 | Stifel | Buy |
| 2024-05-06 | 개시 | H.C. Wainwright | Buy |
| 2024-04-03 | 개시 | Evercore ISI | Outperform |
| 2024-03-28 | 개시 | RBC Capital Mkts | Outperform |
| 2024-03-18 | 개시 | TD Cowen | Outperform |
| 2023-08-11 | 개시 | CapitalOne | Overweight |
| 2022-02-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-11-08 | 개시 | Credit Suisse | Outperform |
| 2021-10-21 | 개시 | William Blair | Outperform |
| 2021-10-20 | 개시 | BMO Capital Markets | Outperform |
| 2021-10-13 | 개시 | Oppenheimer | Outperform |
모두보기
Jasper Therapeutics Inc 주식(JSPR)의 최신 뉴스
Is Jasper Therapeutics Inc. Equity Warrant a good long term investmentFree Technical Analysis Support - PrintWeekIndia
Jasper Therapeutics Inc. Equity Warrant Stock Analysis and ForecastDynamic portfolio growth - PrintWeekIndia
Is Jasper Therapeutics Inc. a good long term investmentJaw-dropping returns - Autocar Professional
What drives Jasper Therapeutics Inc. stock pricePhenomenal capital appreciation - PrintWeekIndia
What analysts say about Jasper Therapeutics Inc. stockHigh-octane financial growth - Autocar Professional
Jasper Therapeutics Inc. Stock Analysis and ForecastHigh-profit trading signals - Autocar Professional
Trading (JSPR) With Integrated Risk Controls - news.stocktradersdaily.com
What analysts say about Jasper Therapeutics Inc. Equity Warrant stockUnrivaled growth potential - jammulinksnews.com
What drives Jasper Therapeutics Inc. Equity Warrant stock priceAccelerated earnings growth - jammulinksnews.com
Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - GlobeNewswire Inc.
Jasper Therapeutics’ SWOT analysis: briquilimab stock faces pivotal moment - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc.JSPR - cnhinews.com
Finance Watch: Karyopharm Cuts Jobs In Cash Crunch; Pacira’s Layoffs Attributed To Efficiency - insights.citeline.com
Bay Area biotech company's drug mishap leads to dozens of layoffs - SFGATE
HC Wainwright Issues Positive Estimate for JSPR Earnings - Defense World
Jasper Therapeutics' Data Crisis and the Investor's Dilemma: Fraud or Unfortunate Setback? - AInvest
Jasper Therapeutics price target lowered to $12 from $70 at Citizens JMP - MSN
Redwood City's Jasper Therapeutics Valuation Tumbles Amid Clinical Trial Setbacks and Layoffs - Hoodline
Jasper Therapeutics shares fall 1.99% after-hours as Schall Law Firm investigates securities law violations. - AInvest
JSPR Investors Have Opportunity to Join Jasper Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Jasper Therapeutics stock holds Market Outperform rating at JMP despite setback - Investing.com Canada
Jasper Therapeutics Announces Major Corporate Reorganization - The Globe and Mail
BMO Capital Markets Reaffirms “Market Perform” Rating for Jasper Therapeutics (NASDAQ:JSPR) - Defense World
Jasper Therapeutics cuts workforce by 50% to focus on urticaria programs - Investing.com South Africa
Where are the Opportunities in (JSPR) - news.stocktradersdaily.com
Peninsula biotech Jasper Therapeutics to lay off half its staff as cash runs lowSan Francisco Business Times - The Business Journals
Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway - MarketScreener
Jasper Therapeutics: A Strategic Gamble on Capital Efficiency and Clinical Focus Ahead of Pivotal Data - AInvest
Jasper Therapeutics falls after halting clinical programs - TradingView
Jasper Therapeutics Announces 50% Workforce Reduction And Strategic Refocus On Chronic Urticaria Programs To Extend Cash Runway And Advance Briquilimab Development - 富途牛牛
Jasper Therapeutics Announces 50% Workforce Reduction and Leadership Change to Enhance Focus on Chronic Urticaria Programs - Nasdaq
Jasper Therapeutics Slashes Workforce by Half, Pivots All Resources to Promising Urticaria Treatment - Stock Titan
Jasper Therapeutics (NASDAQ:JSPR) Price Target Lowered to $20.00 at HC Wainwright - Defense World
BMO Capital Downgrades Jasper Therapeutics to Market Perform From Outperform, Cuts Price Target to $4 From $15 - MarketScreener
Jasper Therapeutics (NASDAQ:JSPR) Given “Market Perform” Rating at William Blair - Defense World
Jasper Therapeutics (NASDAQ:JSPR) Stock Rating Lowered by Cantor Fitzgerald - Defense World
Jasper Therapeutics Gets Hit With Downgrades Over Faulty Batch Of Skin Allergy Drug; Retail Sees ‘Overreaction’ - Stocktwits
Jasper Therapeutics: Manufacturing Setbacks vs. Clinical Promise – Is This a Buying Opportunity? - AInvest
Jasper Therapeutics stock plummets as BTIG slashes price target on trial issues - Investing.com Canada
Cantor Fitzgerald downgrades Jasper Therapeutics stock on clinical trial setback - Investing.com Canada
Jasper Therapeutics stock downgraded by BMO Capital on CSU trial concerns - Investing.com Canada
Jasper Therapeutics stock price target lowered to $20 by Evercore ISI - Investing.com Canada
Jasper Therapeutics Inc: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - investchronicle.com
Jasper Therapeutics stock rating reiterated at Buy by TD Cowen despite trial delay - Investing.com Canada
Jasper Therapeutics stock downgraded by William Blair on drug trial setbacks - Investing.com Canada
Biotech Co. Still a Buy Despite Manufacturing Setbacks - streetwisereports.com
Why Is Jasper Therapeutics Stock Falling On Monday?Jasper Therapeutics (NASDAQ:JSPR) - Benzinga
Jasper Therapeutics Inc (JSPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):